Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

AMSTERDAM, November 30 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.

"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr. Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."

"As the pioneer of ATIR(TM) I am very excited about this next major development milestone, a multinational registration study" says Dr. Denis Claude Roy of the University of Montreal. "I am a strong believer that ATIR(TM) will open up a whole new treatment field for a very large patient group which currently has no treatment options left."

About ATIR(TM)

ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... from Phase II Study Shows 71% Objective Tumor Response Rate ... , - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median ... , ORLANDO, Fla. and TUSTIN, Calif., June 1 Peregrine ... preliminary results from a Phase II trial of its lead ...
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics announced today that promising results from ongoing clinical studies ... presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 ... 2, in Orlando, Florida. , , (Logo: ... , , "We are delighted with the depth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
(Date:7/10/2014)... Institute for Basic Science (IBS), the main organization of ... Korea, has announced that a group of researchers, led ... technology in the field of optogenetics that can remotely ... new technology "OptoTrk" and it has succeeded with neuronal ... technology is that it requires only light to activate ...
(Date:7/10/2014)... soap might not be ape friendly, and the situation appears ... the Cell Press journal Current Biology on July ... led to the conversion of Southeast Asian forest into oil ... are not put in place very soon, researchers say the ... will be bad news for great apes there as well. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
... Pop Quiz: what creatures make up more than 70% ... and have long served as model organisms in many ... To begin exploring this question, a new ... was formed and held its inaugural workshop at Nova ...
... are sensitive to social influences but they maintain their ... to what the majority of group members are doing. ... obtain greater rewards, MPI researchers found. ... a rich palette of learning behaviour, both individually and ...
... (UH) Case Medical Center Seidman Cancer Center and Case ... how changes in the genetic composition of breast cancer ... chemotherapy can predict future clinical outcomes in patients. ... reduction in the most commonly mutated genes in breast ...
Cached Biology News:New organization brings together top researchers to sequence genomes of invertebrates 2New organization brings together top researchers to sequence genomes of invertebrates 3Chimpanzees are rational, not conformists 2Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: